Gregory Schwartz

Summary

Country: USA

Publications

  1. ncbi request reprint Lipid lowering in acute coronary syndromes: new evidence, new questions
    Gregory G Schwartz
    Cardiology Section, 111B, Denver VA Medical Center, 1055 Clermont Street, Denver, CO 80220, USA
    Curr Atheroscler Rep 4:1-3. 2002
  2. doi request reprint Effects of dalcetrapib in patients with a recent acute coronary syndrome
    Gregory G Schwartz
    Cardiology Section, Veterans Affairs Medical Center and University of Colorado School of Medicine, Denver, 80220, USA
    N Engl J Med 367:2089-99. 2012
  3. doi request reprint New horizons for cholesterol ester transfer protein inhibitors
    Gregory G Schwartz
    VA Medical Center and University of Colorado, Denver, CO 80220, USA
    Curr Atheroscler Rep 14:41-8. 2012
  4. doi request reprint High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
    Gregory G Schwartz
    VA Medical Center, University of Colorado, Denver, USA
    Am Heart J 161:993-9. 2011
  5. doi request reprint Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
    Gregory G Schwartz
    VA Medical Center and University of Colorado, Denver, CO 80220, USA
    Am Heart J 158:896-901.e3. 2009
  6. doi request reprint High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome
    Gregory G Schwartz
    CardiologySection 111B, Veterans Affairs Medical Center, 1055 Clermont Street, Denver, Colorado 80220, USA
    Am J Cardiol 104:46E-51E. 2009
  7. ncbi request reprint Lipid management after acute coronary syndrome
    Gregory G Schwartz
    VA Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    Curr Opin Lipidol 18:626-32. 2007
  8. ncbi request reprint Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
    Gregory G Schwartz
    Cardiology Section, VA Medical Center, Denver, Colorado 80220, USA
    Diabetes Care 28:2508-13. 2005
  9. ncbi request reprint The case for intensive statin therapy after acute coronary syndromes
    Gregory G Schwartz
    Cardiology Section, Veterans Affairs Medical Center, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Am J Cardiol 96:45F-53F. 2005
  10. ncbi request reprint Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial
    Gregory G Schwartz
    University of Colorado, Denver VA Medical Center, Denver, Colo 80220, USA
    Am Heart J 148:e4. 2004

Research Grants

Detail Information

Publications24

  1. ncbi request reprint Lipid lowering in acute coronary syndromes: new evidence, new questions
    Gregory G Schwartz
    Cardiology Section, 111B, Denver VA Medical Center, 1055 Clermont Street, Denver, CO 80220, USA
    Curr Atheroscler Rep 4:1-3. 2002
  2. doi request reprint Effects of dalcetrapib in patients with a recent acute coronary syndrome
    Gregory G Schwartz
    Cardiology Section, Veterans Affairs Medical Center and University of Colorado School of Medicine, Denver, 80220, USA
    N Engl J Med 367:2089-99. 2012
    ..Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes...
  3. doi request reprint New horizons for cholesterol ester transfer protein inhibitors
    Gregory G Schwartz
    VA Medical Center and University of Colorado, Denver, CO 80220, USA
    Curr Atheroscler Rep 14:41-8. 2012
    ..Two large cardiovascular outcomes trials, one with anacetrapib and one with dalcetrapib, should provide a conclusive test of the hypothesis that inhibition of CETP decreases cardiovascular risk...
  4. doi request reprint High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
    Gregory G Schwartz
    VA Medical Center, University of Colorado, Denver, USA
    Am Heart J 161:993-9. 2011
    ..We tested the hypothesis that long-term treatment with high-dose atorvastatin reduces occurrence of AF in patients with prior stroke or transient ischemic attack...
  5. doi request reprint Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
    Gregory G Schwartz
    VA Medical Center and University of Colorado, Denver, CO 80220, USA
    Am Heart J 158:896-901.e3. 2009
    ..Dal-OUTCOMES is a multicenter, randomized, double-blind, placebo-controlled trial designed to test the hypothesis that CETP inhibition with dalcetrapib reduces cardiovascular morbidity and mortality in patients with recent ACS...
  6. doi request reprint High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome
    Gregory G Schwartz
    CardiologySection 111B, Veterans Affairs Medical Center, 1055 Clermont Street, Denver, Colorado 80220, USA
    Am J Cardiol 104:46E-51E. 2009
    ..Clinical trials are in progress to test the hypothesis that strategies to raise levels of HDL cholesterol will reduce risk after ACS...
  7. ncbi request reprint Lipid management after acute coronary syndrome
    Gregory G Schwartz
    VA Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    Curr Opin Lipidol 18:626-32. 2007
    ..Interventions targeting atherogenic lipoproteins may favorably modify this risk...
  8. ncbi request reprint Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
    Gregory G Schwartz
    Cardiology Section, VA Medical Center, Denver, Colorado 80220, USA
    Diabetes Care 28:2508-13. 2005
    ..We examined relations between characteristics of the metabolic syndrome, early cardiovascular risk, and effect of early, intensive statin therapy after acute coronary syndrome...
  9. ncbi request reprint The case for intensive statin therapy after acute coronary syndromes
    Gregory G Schwartz
    Cardiology Section, Veterans Affairs Medical Center, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Am J Cardiol 96:45F-53F. 2005
    ..Moreover, evidence suggests that anti-inflammatory effects of high-intensity statin treatment are associated with clinical benefit...
  10. ncbi request reprint Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial
    Gregory G Schwartz
    University of Colorado, Denver VA Medical Center, Denver, Colo 80220, USA
    Am Heart J 148:e4. 2004
    ..This double-blind, multicenter, randomized trial compared rosuvastatin and atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and a high risk of coronary heart disease...
  11. ncbi request reprint Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes
    Gregory G Schwartz
    Veterans Administration Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    Am J Cardiol 92:1109-12. 2003
    ..The net incremental cost of atorvastatin treatment was 157 dollars/patient with a cost-effectiveness ratio of 4,086 dollars/event avoided...
  12. pmc Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs
    Ya Xu
    VA Medical Center and University of Colorado Health Sciences Center, Denver, CO, USA
    Diabetes 52:1187-94. 2003
    ..Acute treatment with troglitazone increases susceptibility to ventricular fibrillation during myocardial ischemia and reperfusion. Whether thiazolidinediones have proarrhythmic potential in clinical use requires further investigation...
  13. pmc Multiple abnormalities of myocardial insulin signaling in a porcine model of diet-induced obesity
    Jenny Lee
    Veterans Affairs Medical Center, University of Colorado, Denver, Colorado, USA
    Am J Physiol Heart Circ Physiol 298:H310-9. 2010
    ....
  14. ncbi request reprint Early initiation of treatment with statins in acute coronary syndromes
    Anders G Olsson
    Faculty of Health Sciences, University of Linkoping, Sweden
    Ann Med 34:37-41. 2002
    ..The studies highlight the importance of treatment with a statin in the early management of acute coronary syndromes and the need to incorporate this therapeutic strategy in national guidelines and treatment recommendations...
  15. ncbi request reprint Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy
    David D Waters
    Division of Cardiology, San Francisco General Hospital, and the University of California, San Francisco School of Medicine, San Francisco, Calif 94110, USA
    Circulation 106:1690-5. 2002
    ..4% in the placebo group to 14.8% in the atorvastatin group over the 16 weeks of the trial (P=0.048)...
  16. ncbi request reprint High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
    Scott Kinlay
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:1560-6. 2003
    ..Although statins reduce inflammatory markers in asymptomatic adults or in patients with stable angina, the effect of statins on the markedly heightened inflammation in patients with acute coronary syndromes is unknown...
  17. ncbi request reprint Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study
    Scott Kinlay
    Cardiovascular Division, Veterans Affairs Boston Healthcare System, West Roxbury, Mass, USA
    Arterioscler Thromb Vasc Biol 28:142-7. 2008
    ..We measured markers of inflammation in the MIRACL study, a randomized trial of atorvastatin versus placebo in acute coronary syndromes, to assess the relationship of inflammation to stroke...
  18. ncbi request reprint Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study)
    Anders G Olsson
    Faculty of Health Sciences, University of Linkoping, Linkoping, Sweden
    Am J Cardiol 99:632-5. 2007
    ..In conclusion, these results and a greater immediate cardiovascular risk in older patients argue for early, intensive atorvastatin therapy as routine practice after ACS...
  19. ncbi request reprint Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials
    Matthias Briel
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Basel, Switzerland
    JAMA 295:2046-56. 2006
    ..The short-term effects of early treatment with statins in patients after the onset of acute coronary syndromes (ACS) for the outcomes of death, myocardial infarction (MI), and stroke are unclear...
  20. ncbi request reprint Statins in acute coronary syndromes: the sooner, the better?
    Gregory G Schwartz
    Am Heart J 149:377-80. 2005
  21. ncbi request reprint High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial
    Anders G Olsson
    Department of Medicine and Care, Internal Medicine, University of Linkoping, SE 58185 Linkoping, Sweden
    Eur Heart J 26:890-6. 2005
    ..We determined whether plasma lipoproteins at baseline and then at 6 weeks after randomization predicted clinical outcome...
  22. ncbi request reprint High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial
    Sotirios Tsimikas
    Vascular Medicine Program, Department of Medicine, University of California San Diego, 9500 Gilman Dr, BSB 1080, La Jolla, CA 92093 0682, USA
    Circulation 110:1406-12. 2004
    ..This study evaluated the impact of atorvastatin on oxidized LDL (OxLDL) in patients with acute coronary syndromes (ACS)...
  23. ncbi request reprint Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study
    Scott Kinlay
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 110:386-91. 2004
    ..Statins inhibit CD40L signaling in vitro, but there are no prospective studies of statins and sCD40L in acute coronary syndromes...
  24. ncbi request reprint Perioperative beta-blockade: a survey of physician attitudes in the department of Veterans Affairs
    Martin J London
    Department of Anesthesia and Perioperative Care, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA
    J Cardiothorac Vasc Anesth 18:14-24. 2004
    ..To delineate clinician opinion on the efficacy, safety, and logistics of perioperative beta-adrenergic blockade for patients undergoing noncardiac surgery...

Research Grants7

  1. Protection by Thiazolidinediones in Myocardial Ischemia
    Gregory Schwartz; Fiscal Year: 2006
    ....
  2. Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
    Gregory Schwartz; Fiscal Year: 2009
    ..Using pigs, this study will determine the ways in which the use of sugars and fats by the heart is altered in insulin resistance, leading to poorer cardiac function after heart attack. ..
  3. Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
    Gregory G Schwartz; Fiscal Year: 2010
    ..Using pigs, this study will determine the ways in which the use of sugars and fats by the heart is altered in insulin resistance, leading to poorer cardiac function after heart attack. ..